• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AlzChem Group (XTRA:ACT) Could Be 25% Undervalued As Strong 2026 Earnings Land

    Simply Wall St·07/31/2026 16:22:09
    Listen to the news

    AlzChem Group (XTRA:ACT) has drawn fresh attention after reporting second quarter and first half 2026 results, with both sales and net income higher than the same periods a year earlier.

    See our latest analysis for AlzChem Group.

    Despite the stronger first half of 2026 results, AlzChem Group’s share price has fallen 11.6% over the past day and is down 12.3% over the past week, although the 5 year total shareholder return of over 6x points to a much stronger longer term picture.

    If this earnings move has you reassessing your watchlist, it could be a useful moment to scan other opportunities in materials and related sectors through the 29 best rare earth metal stocks

    The earnings news for AlzChem Group is strong while the share price has just dropped. Some investors may see this as a chance to buy after the pullback, while others may prefer to wait for a clearer entry based on valuation.

    Most Popular Narrative: 24.7% Undervalued

    The most followed narrative currently places AlzChem Group’s fair value at €204.49, compared with the latest close at €153.90. That gap relies heavily on how earnings and margins are expected to evolve over the next few years.

    AlzChem's accelerated capacity expansions in Specialty Chemicals, particularly in high-margin products like creatine and nitroguanidine, position the company to capitalize on global demand shifts toward advanced materials and specialty nutrition, supporting both top-line growth and structural improvement in group net margins.

    Read the complete narrative.

    Curious what kind of revenue climb and margin profile would support that higher fair value? The narrative leans on steady expansion, a richer mix, and a specific earnings path. The detailed model also hinges on a future valuation multiple that assumes investor confidence holds up.

    Result: Fair Value of €204.49 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you still need to weigh risks such as EU regulation around calcium cyanamide fertilizer and pressure from lower cost competitors that could challenge the AlzChem Group narrative.

    Find out about the key risks to this AlzChem Group narrative.

    Next Steps

    With both risks and rewards in play for AlzChem Group, this is a good moment to review the details yourself and act promptly. To see that balance at a glance, start with the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond AlzChem Group?

    Do not stop with a single stock story. Use this moment to widen your net and pressure test your thinking against other ideas across sectors and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.